Logo image of IMRX

IMMUNEERING CORP - CLASS A (IMRX) Stock Analyst Ratings

NASDAQ:IMRX - Nasdaq - US45254E1073 - Common Stock - Currency: USD

2.11  0 (0%)

Buy % Consensus

78

ChartMill assigns a Buy % Consensus number of 78% to IMRX. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 12.67. This target is 500.24% above the current price.
IMRX was analyzed by 13 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about IMRX.
In the previous month the buy percentage consensus was at a similar level.
IMRX was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
IMRX Historical Analyst RatingsIMRX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -40 -36 -32 -28 -24 -20 -16 -12 -8 -4 0 5 10

Price Target & Forecast

Price Low Median Mean High 2.111.5212.7512.6726.25 - -28.20% 504.27% 500.24% 1,144.08%
IMRX Current Analyst RatingIMRX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6
Up and Down Grades
Date Firm Action Rating
2025-01-13 Needham Reiterate Buy -> Buy
2025-01-08 Chardan Capital Maintains Buy -> Buy
2025-01-07 Needham Reiterate Buy -> Buy
2024-11-20 Chardan Capital Maintains Buy -> Buy
2024-11-14 Needham Reiterate Buy -> Buy
2024-09-13 Needham Reiterate Buy -> Buy
2024-08-07 Chardan Capital Maintains Buy -> Buy
2024-08-07 Needham Reiterate Buy -> Buy
2024-05-08 Needham Reiterate Buy -> Buy
2024-04-12 Needham Reiterate Buy -> Buy
2024-04-02 Mizuho Maintains Buy -> Buy
2024-03-15 TD Cowen Downgrade Outperform -> Market Perform
2024-03-15 Chardan Capital Maintains Buy -> Buy
2024-03-15 Needham Maintains Buy -> Buy
2024-03-15 Jefferies Downgrade Buy -> Hold
2024-03-14 Guggenheim Downgrade Buy -> Neutral
2024-03-11 Needham Reiterate Buy -> Buy
2024-03-05 Oppenheimer Reiterate Outperform -> Outperform
2024-03-04 Needham Reiterate Buy -> Buy
2024-02-01 Needham Reiterate Buy -> Buy
2023-12-01 Needham Initiate Buy
2023-08-08 Oppenheimer Reiterate Outperform -> Outperform
2023-08-07 Chardan Capital Reiterate Buy -> Buy
2023-08-04 Morgan Stanley Maintains Equal-Weight -> Equal-Weight
2023-04-19 Chardan Capital Maintains Buy
2023-04-19 Mizuho Upgrade Neutral -> Buy
2023-04-19 Morgan Stanley Upgrade Underweight -> Equal-Weight
2023-04-18 Chardan Capital Maintains Buy
2023-03-30 Mizuho Initiate Neutral
2023-03-07 Chardan Capital Reiterate Buy